Terrance H. Gregg has been CEO of Dexcom, Inc. since 2011. He first joined the Dexcom Board of Directors in 2005. Click on “Show More” to see a timestamped list with all the questions.
In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic’s $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.
Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association. In 2010, Mr. Gregg and his wife were recognized by the Juvenile Diabetes Research Foundation (JDRF) with one of it’s highest honors, the 2010 Angel Award. Most recently, Mr. Gregg was honored as one of the San Diego regional finalists for the Ernst and Young Entrepreneur of the Year Award 2011 and named by MassDevice.com, one of 28 chief executives whom exemplify cutting-edge leadership and innovative thinking in the medical device industry, as its inaugural CEO Class of 2011.
Mr. Gregg currently serves on several advisory boards, including Scripps Translational Science Institute and the University of Miami Diabetes Research Institute (DRI). Additionally Mr. Gregg sits on the board of directors of Taking Control of Your Diabetes, a non-profit educational program.
In case there are specific topics you would like to hear in this talk, but don’t want to watch the whole viedo to find them, here’s a list of what’s covered with the time at which each topic came up:
What’s next for Dexcom? What companies are they working with? 5:17
How will Gen 5 differ from Gen 4? 6:44
What’s “Share”? 7:38 and 37:08
What will be new about Gen 6? 8:39
Why does Terry do what he does? 10:08
Do you have a personal connection to diabetes? 11:10
Will the Gen 5 transmitter be larger than the Gen 4? 13:04
What’s the status of Dexcom CGM integration with insulin pumps from different companies you are collaborating with? 15:57
What’s about a protective case for the Gen 4 receiver? 21:25
What critical feedback are you getting about the Gen 4 so far? 23:03
When will the Dexcom CGM be available in Canada? 24:01
Are the calibration requirements different for the Gen 4 than the 7+ CGM? 27:29
How will people who have the Gen 4 upgrade to subsequent generations? 27:52
What is Dexcom Inc. doing to make its technology available to people without Health Insurance, on Medicare, and with few financial resources? 28:47
Is there anything useful that people who upgrade from the 7+ to the Gen 4 can do with unused 7+ sensors? 31:40
Will glucosensor technology be available to the general public eventually? 33:50
How were the colors for the high and low limits decided upon? 34:50
How can patients get involved in trials to test Dexcom products? 35:45
Do you anticipate difficulty getting FDA to approve Gen 5 because it connects to a cell phone? 39:59
Is the iPhone intended to be the primary mode of monitoring in Gen 5? 43:10
Once Gen 5 comes out, will there be an optional receiver available to people who do not own smart phones? 45:13
Will later generations of the Dexcom CGM allow greater customization of the alarms, or enable it to link to an external device with louder volume options? 46:39
Will cellphone battery life and multiple platform compatibility be problems in using the phone as receiver? 48:04
Will it be possible to use an external receiver (cellphone) with the Vibe? 49:41
Are there plans to make the receiver smaller? 50:10
Is Dexcom working on software for Mac? 51:29
We want an orange receiver! Can you make one? 53:09
Will the Gen 6 sensor be better able to tollerate acetaminophen? 53:42